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was conducted. RESULTS: Overall, 20,488 cases were included in the analysis. After         
the adjustment for age, sex, body-mass-index and duration of education there is a 
statistically signiﬁcant association between consumption of tobacco and HRQoL in 
all subscores as well as both composite scores of the SF-12. The regression coefﬁcients 
for current smoking (all non-smokers as reference group) are relatively small with 
0.68 (role physical) to 1.35 (general health) points for physical domains and 
between 0.58 (vitality) and 1.47 (mental health) points for mental domains. These 
differences increase considerable for elderly persons (age of 50 or older, N  9830) 
with 1.274 (role physical) to 1.87 (general health) points for physical and 0.953 
(vitality) to 1.682 (social functioning) for mental scales. Equally, there is a strong 
statistical association between the current amount of smoking (per 10 cigarettes per 
day) and HRQoL (0.342 to 0.858 for physical and 0.47 to 1.07 for mental 
domains, N  5560). CONCLUSIONS: In particular, the ﬁndings are limited by the        
inconclusive causality direction for smoking and mental health. However, these results 
conﬁrm the existing evidence concerning the negative association between smoking 
status or smoking intensity and HRQoL in a general population.
PRS39
VALIDATION OF THE SPANISH VERSION OF THE “COPD AND 
ASTHMA SLEEP IMPACT SCALE (CASIS)” QUESTIONNAIRE
Lahoz R1, Galera J1, Lleonart M1, Miravitlles M2
1Novartis Pharmaceuticals, Barcelona, Spain, 2Hospital Clínic, Barcelona, Spain
OBJECTIVES: To validate the Spanish version of the speciﬁc questionnaire “COPD 
and asthma sleep impact scale (CASIS)” which measures the impact of sleep quality 
in patients with COPD on their HRQoL. METHODS: Observational, prospective, 
multicenter study in patients with moderate/severe COPD. Data were collected at 
inclusion and at day 15, including the Spanish version of CASIS (7 items, range: 7 
best–35 worst) and the “gold standard” Saint George Respiratory Questionnaire 
(SGRQ). Additionally, socio-demographics, clinical data and one item about self-
 perceived change in health status between visits were recorded. Feasibility, validity, 
reliability (internal consistency, test-retest) and responsiveness to change of the CASIS 
Spanish version were evaluated. RESULTS: A total of 142 patients were included, 
87.1% males, mean age (SD) was 67.4(8.2) years, 52.7% with primary studies, 75% 
former smokers, FEV1 (%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 
11.1% stage IV. Mean (SD) score in CASIS was 18.5(6.5). CASIS questionnaire 
showed low levels of absent information: the mean number of items not responded 
per patient was 0.1, and no item accumulated more than 1 missing response. Ceilling 
effects of CASIS (proportion of patients accumulated in the maximum possible score) 
were null, and ﬂoor effects (proportion of patients accumulated in the minimum pos-
sible score) were 7.5%. CASIS showed low internal consistency (Cronbach’s alpha 
0.50) but an excellent test-retest reliability among patients who reported subjective 
stability in their health status (inter-class correlation coefﬁcient  0.88). Correlations 
between CASIS and SGRQ global scores were high (0.71) and correlations between 
CASIS and SGRQ dimensions were moderate to high (0.62 to 0.69). Signiﬁcant dif-
ferences (p  0.01) in LCOPD were observed in exacerbated patients who reported 
an improvement, with a high effect size (0.90). CONCLUSIONS: According to pre-
liminary results, Spanish version of CASIS showed satisfactory psychometric proper-
ties in terms of feasibility, validity, reliability and responsiveness to change.
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OBJECTIVES: It is hypothesised that cough and/or sputum symptoms have a negative 
impact on health-related quality of life (HRQoL) in chronic obstructive pulmonary 
disease (COPD). This study assessed the impact of these symptoms on HRQoL in 396 
COPD patients. METHODS: Data were drawn from the Respiratory Adelphi Disease 
Speciﬁc Programme conducted in France, Germany, Italy, Spain, the UK and the USA 
in 2008. Information collected included physicians’ perceptions of symptom severity. 
Patients were invited to ﬁll out a questionnaire that included EQ-5D. Variables anal-
ysed were age, gender, body mass index, breathlessness, smoking status, co-morbidi-
ties (heart-related and anxiety/depression), compliance, most recent forced expiratory 
volume in 1 second (FEV1, if available) and country of origin. Due to a highly skewed 
EQ-5D distribution, three regression methods were applied (Tobit, OLS and GLM) 
to assess the impact of these variables on HRQoL. Final models derived included sta-
tistically signiﬁcant variables only (p  0.05). RESULTS: Using all three methods, 
cough and/or sputum were signiﬁcant predictors of worse HRQoL compared with 
COPD patients not experiencing these symptoms. FEV1 was only a signiﬁcant predic-
tor of better HRQoL in the Tobit approach. In this model, patients with moderate or 
severe cough and/or sputum symptoms presented with worse HRQoL compared with 
the wider COPD population (-0.09, 95% CI 0.14, 0.04). FEV1 values 30–50% 
predicted are associated with higher EQ-5D (0.006, p  0.05). However, no further 
signiﬁcant impact was present at FEV1 50% predicted. In the Tobit model, patients 
not viewed as fully compliant with the current drug regimen were also associated with 
worse EQ-5D (0.09, p  0.05). Similar statistically signiﬁcant variables were observed 
using the GLM and OLS models. CONCLUSIONS: Presence and severity of cough 
and/or sputum in COPD has a marked association with worse HRQoL, independent 
of FEV1 measurements. These results indicate unmet therapeutic needs in this 
population.
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OBJECTIVES: To validate the Spanish version of the quality of life (QoL) speciﬁc 
questionnaire for patients with COPD “Living with Chronic Obstructive Pulmonary 
Disease” (LCOPD). METHODS: Observational, prospective, multicenter study in a 
sample of patients with moderate/severe COPD. Data were collected at inclusion and 
at day 15, including the Spanish version of LCOPD (22 items, range: 22 worst—44 
best) and the “gold standard” Saint George Respiratory Questionnaire (SGRQ). 
Additionally, socio-demographics, clinical data and one item about self-perceived 
change in health status between visits were recorded. Feasibility, validity, reliability 
(internal consistency, test-retest) and responsiveness to change of the LCOPD Spanish 
version were evaluated. RESULTS: A total of 142 patients were included, 87.1% 
males, mean age (SD) was 67.4 (8.2) years, 52.7% with primary studies, 75% former 
smokers, FEV1 (%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 11.1% 
stage IV. Mean (SD) score in LCOPD was 33.0 (6.7). LCOPD questionnaire showed 
low levels of absent information: the mean number of items not responded per patient 
was 0.1, and no item accumulated more than 1 missing response. Floor and ceiling 
effects of LCOPD (proportion of patients accumulated in the minimum and maximum 
possible scores, respectively), were low (6%). LCOPD showed satisfactory levels of 
reliability: high internal consistency (Cronbach’s alpha  0.94) and excellent test-retest 
reliability among patients who reported subjective stability in their health status (inter-
class correlation coefﬁcient  0.92, p  0.001). Correlations between LCOPD and 
SGRQ global scores were very high (0.85), and correlations between LCOPD and 
SGRQ dimensions were moderate to high (0.60 to 0.87). Signiﬁcant differences (p  
0.05) in LCOPD were observed in exacerbated patients who reported an improvement, 
with a small to moderate effect size (0.31). CONCLUSIONS: According to preliminary 
results, Spanish version of LCOPD showed satisfactory psychometric properties in 
terms of feasibility, validity, reliability and responsiveness to change.
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OBJECTIVES: To validate the Spanish version of the health speciﬁc questionnaire to 
evaluate the impact of fatigue on patients with COPD “COPD and asthma fatigue 
scale (CAFS)”. METHODS: Observational, prospective, multicenter study in a sample 
of patients with moderate/severe COPD. Data were collected at inclusion and at day 
15, including the Spanish version of CAFS (12 items, range: 12 best–60 worst) and 
the “gold standard” Saint George Respiratory Questionnaire (SGRQ). Additionally, 
socio-demographics, clinical data and one item about self-perceived change in health 
status between visits were recorded. Feasibility, validity, reliability (internal consis-
tency, test-retest) and responsiveness to change of the CAFS Spanish version were 
evaluated. RESULTS: A total of 142 patients were included, 87.1% males, mean age 
(SD) was 67.4 (8.2) years, 52.7% with primary studies, 75% former smokers, FEV1 
(%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 11.1% stage IV. Mean 
(SD) score in CAFS was 36.7 (12.1). CAFS questionnaire showed low levels of absent 
information: the mean number of items not responded per patient was 0.1, and no 
item accumulated more than 1 missing response. Floor and ceiling effects of CAFS 
(proportion of patients accumulated in the minimum and maximum possible scores, 
respectively), were low (2%). CAFS showed satisfactory levels of reliability: high 
internal consistency (Cronbach’s alpha  0.88) and excellent test-retest reliability 
among patients who reported subjective stability in their health status (inter-class 
correlation coefﬁcient  0.85). Correlations between CAFS and SGRQ global scores 
were high (0.79), such as the correlations between CAFS and SGRQ dimensions (0.63 
to 0.74). Signiﬁcant differences (p  0.01) in LCOPD were observed in exacerbated 
patients who reported an improvement, with a high effect size (0.90). CONCLU-
SIONS: According to preliminary results, Spanish version of CAFS showed satisfactory 
psychometric properties in terms of feasibility, validity, reliability and responsiveness 
to change.
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Smoker Complaint Scale for the Turkish population. METHODS: The research 
was conducted in the university students. For pretest study forty students were chosen 
as a sampling group. After the assessment of the results, the Smoker Complaint Scale 
was applied to 250 students who quit smoking. Of the students are 54% female and 
46% male. The original instrument was translated into Turkish and then translated 
back into English by two independent translators. For psychometric measures, a small 
sample was used to check the initial comprehension and factibility. Cronbach’s Alfa 
was used to assess reliability and factor analysis to assess dimensionality. The 
EuroQol-5D was used for concurrent validity. RESULTS: The internal consistency 
coefﬁcient (Cronbach’s alpha) of SCS was 0.912. Factor analysis of the scale revealed 
that it was composed of 5 factors with Eigenvalues 1.0, accounting for 77.9% of the 
total variance. All the items of the Turkish SCS had a factor load ranging from 0.587 
